INTRODUCTION
Cyclophilins were first identified as the high-affinity binding proteins for the immunosuppressive drug cyclosporin A (CsA). CsA is a cyclic undecapeptide which was isolated over 20 years ago based on its ability to inhibit a mixed lymphocyte reaction [1] . Its clinical introduction greatly improved the outcome of solid organ and bone-marrow transplantation and, despite toxic side-effects, it remains a widely used immunosuppressive agent [2] . Cyclophilins are members of the peptidyl prolyl cis-trans isomerase family, which includes also the FK506-binding proteins (FKBPs) [3] and the parvulins [4] . The FKBPs are able to bind the macrolide FK506, which is also used to prevent graft rejection but is structurally unrelated to CsA [5] . All these proteins catalyse the prolyl bond isomerization rate of synthetic peptides and the refolding of a few denatured proteins [3, [6] [7] [8] . CsA inhibits cyclophilin prolyl isomerase activity [8] , while FK506 inhibits FKBP prolyl isomerase activity [3] .
Several cyclophilin isoforms with distinct subcellular localizations have been described in various prokaryotic and eukaryotic organisms. The first form characterized is cyclophilin A (CyPA), an abundant cytosolic protein which is considered to be the main target of CsA in i o [9] . Indeed, the complex formed by the immunosuppressive drug and CyPA binds and modulates the activity of calcineurin [10] , a critical intermediate in the signal transduction pathway recruited upon T-cell activation [11] . Cyclophilin B (CyPB) [12] [13] [14] and cyclophilin C (CyPC) [15] are related to CyPA but contain an N-terminal signal sequence thought to mediate translocation into the endoplasmic reticulum. Mitochondrial cyclophilin (CyPD) is the fourth member of the human cyclophilin family [16, 17] .
CyPB has been reported as being retained in specialized portions of the endoplasmic reticulum [18] but also as a protein which follows the secretory pathway until its secretion [19] . Its
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receptor. However, when this residue was replaced by an alanine residue using site-directed mutagenesis, no modification of the binding properties was found, suggesting that Arg") is not directly involved but is sufficiently close to the interaction site to interfere with the binding when modified. Competitive binding experiments using a chimaeric protein made up of the 24 Nterminal amino acid residues of CyPB fused to the cyclophilin A core sequence confirmed the involvement of this region of CyPB in receptor binding.
purification from human milk has provided the evidence that CyPB is secreted into this medium [14] . Specific antibodies against peptides corresponding to the most divergent parts between CyPA and CyPB were used to show that CyPB, but not CyPA, is also present in human blood [20] . The binding capacity of CyPB to cells of the immune system was furthermore investigated and indeed surface binding sites characterized on both Jurkat T-cells and human peripheral blood T-lymphocytes. A dissociation constant (K d ) of 12 nM was calculated and the number of binding sites estimated to be 35 000\cell [21] . The CyPB-CsA complex binds to the T-lymphocytes with a similar K d value and to approximately the same number of sites. At 37 mC, both the CyPB-CsA complex and free CyPB are internalized after binding. However, while CyPB is subsequently degraded in acidic compartments, CsA is accumulated within the cell. Thus, over a defined range of CyPB concentrations, the CyPB-CsA complex may target the drug to lymphocytes and increase the cellular concentration of CsA (see the accompanying paper [21a] ). The presence of these surface binding sites is consistent with the hypothesis that CyPB is secreted into biological fluids such as milk or blood [14, 20] and then interacts with specific receptors on target cells.
In an attempt to specify the areas of CyPB that interact with the surface binding sites of Jurkat cells, several competitive binding assays have been carried out. By comparing the amino acid sequence of CyPA, which does not interact with the Jurkat T-cell surface binding sites [21] , and CyPB, it appears that the Nand C-terminal parts of CyPB are specific to this protein and may therefore contain the interaction site. We have therefore investigated the possible involvement of the N-and C-terminal extremities of CyPB in the binding to the Jurkat receptor by competitive experiments using synthetic peptides corresponding to these regions. CyPB mutants modified at specific locations, either chemically or by site-directed mutagenesis, and a CyPB\ CyPA chimaera were furthermore used to gain information on the sites involved in the recognition of the specific receptor. 
EXPERIMENTAL Materials

Construction of CyPB mutants
The CyPB\A chimaera was constructed in two steps. First, the region coding for the N-terminal part of mature CyPB up to Arg#' was amplified by PCR while adding a flanking NcoI site, including the ATG initiator codon, at the 5h side, and flanking MluI and HindIII restriction sites at the 3h end. The MluI site was selected because it was compatible with the desired final amino acid sequence and not present in the original cyclophilin coding sequences. The HindIII site was used, together with NcoI, for subcloning into the pKK233-2 vector (Pharmacia, Uppsala, Sweden), after purification on a low-melting-point agarose (FMC) gel. Secondly, the CyPA coding region from Gly") to the stop codon was amplified by PCR while introducing flanking MluI and HindIII restriction sites. After gel purification and digestion with the appropriate enzymes this fragment was subcloned downstream of the CyPB coding portion in pKK233-2. The resulting plasmid codes for a protein composed of the CyPB-specific N-terminal region (up to Val#%) fused to amino acids Gly") to end residue Glu of CyPA.
For the CyPB L"(I ; R")A construct, the region coding for the Nterminal region of CyPB up to Gly#& was amplified with PCR using the same 5h primer as above and a 3h primer designed so as to introduce the desired mutations while adding flanking AatII and HindIII restriction sites. The AatII site was selected because it was compatible with the desired final amino acid sequence and not present in the original cyclophilin coding sequence. This fragment was subcloned between the NcoI and HindIII sites of pKK233-2. The region coding for the remainder of CyPB was amplified by PCR while introducing flanking AatII and HindIII sites. It was subcloned downstream of the above-mentioned fragment in pKK233-2 to generate a plasmid coding for a mutant form of CyPB where Leu"( and Arg") have been changed to Ile and Ala, respectively.
All the constructs were verified by complete DNA sequencing on the cyclophilin-coding part and the flanking regions, and then used for transformation of competent Escherichia coli. A single colony was picked in each case for the expression studies. Cultures (1.5-3 l) of transformed E. coli were grown at 37 mC to an absorption value at 550 nm of 2. Induction was with 1 mM isopropyl--thiogalactopyranoside for 4 h before harvesting.
Preparation of recombinant wild-type and mutant CyPB
Purifications of recombinant wild-type CyPB and CyPB L"(I ; R")A were performed using the procedure described in [14] . Purification of the CyPB\A chimaera was performed using the same procedure but the ion-exchange chromatography step on a Mono S column was performed at pH 6.0 instead of pH 6.5 due to the lower pI of the protein.
Peptide synthesis
Peptides were synthesized using the conventional solid-phase ' Boc-benzyl strategy ' [22] on ' PAM ' resins [23] in an automated Applied BioSystem 470A peptide synthesizer, using an N,N-dicyclohexylcarbodi-imide\hydroxybenzotriazole-based coupling procedure. After fluorohydric acid cleavage from the resin in the presence of scavengers, crude deprotected peptides were purified by trifluoroacetic acid\diethyl ether precipitation followed by gel permeation.
Derivatization of recombinant CyPB with p-hydroxyphenylglyoxal and AMCA-HPDP
Labelling of CyPB with AMCA-HPDP
A sample (0.536 mg) of AMCA-HPDP was dissolved in 1 ml of DMSO (1.55 mM final concentration). CyPB was diluted in PBS\EDTA (1 mM) to a final concentration of 0.5 mg\ml. CyPB was conjugated with AMCA-HPDP at a molar ratio of reagent to CyPB of 10 : 1. Incubation was performed at room temperature for 90 min. The reaction of AMCA-HPDP with the sulphydryl group of CyPB was followed with spectrophotometry since the reaction leaving group, pyridine-2-thione, has a characteristic absorption at 343 nm. Free AMCA-HPDP was removed by gel filtration on a Sephadex G-25 PD10 column (Pharmacia). The ratio of AMCA-HPDP to CyPB was estimated by measuring the absorbance values at 280 nm and 345 nm according to the instructions of the manufacturer.
Modification of arginine residues with p-hydroxyphenylglyoxal
An aliquot (0.5 mg) of CyPB (or CyPB L"(I ; R")A or *D"EKKKG-PKVTVKVYFDLRIGDEDV#% peptide) was reacted with 0.5 mg of p-hydroxyphenylglyoxal in 0.5 ml of 0.1 M sodium borate buffer, pH 9.0. The reaction mixture was incubated for 1 h at 25 mC in the dark. The excess of p-hydroxyphenylglyoxal was eliminated by gel filtration on a Sephadex G-25 PD10 column (Pharmacia) for CyPB and on a Sephadex G-10 column (1.5 cmi10 cm) for the D"EKKKGPKVTVKVYFDLRIG-DEDV#% peptide. The content of modified arginine residues was estimated based on the molar absorption coefficient for the product. Modified arginine residues exhibit a maximum absorbance at 335 nm with a molar absorption coefficient of 1.85i10% M −" :cm −" at pH 9.0 [24] .
Cells
The human lymphoblastic T-cell line Jurkat was routinely cultured in RPMI 1640 medium (Life Technologies, Inc.) containing 2 mM -glutamine, 20 mM Hepes, 25 mM NaHCO $ and 5 µg\ml gentamicin (pH 7.3), supplemented with 10 % heatinactivated fetal calf serum. The culture was diluted every 2 days in order to maintain a cell concentration ranging from 0.5i10' to 1i10' cells\ml.
Competition binding assays
"#&I-CyPB was obtained by incubating 100 µg of protein with 0.3 mCi of carrier-free Na"#&I (ICN Biochemicals, Costa Mesa, U.S.A.) in the presence of 100 µg of Iodo-Gen (Pierce, Rockford, U.S.A.) for 15 min at room temperature. Free iodine was removed by gel filtration on a Sephadex G-25 PD10 column. The specific radioactivity was approx. (2-3)i10' c.p.m.\µg.
The cells were washed twice and diluted in Dulbecco's PBS (DPBS)-0.5 % BSA to a final concentration of 4i10' cells\ml. The specificity of CyPB binding was studied by incubating Jurkat T-cells (2i10' cells\sample) with 25 nM "#&I-CyPB and a molar excess of competitors for 1 h at 4 mC. After incubation, the cells were centrifuged (400 g, 5 min) and washed three times with 3 ml of cold DPBS. Cell-associated radioactivity was measured using a model 1282 Compugamma LKB-Wallac counter.
RESULTS
Competitive binding assays with cyclophilin isoforms
The specificity of CyPB binding to Jurkat T-cells was examined by competitive binding experiments in the presence of two other cyclophilins, CyPA and CyPC. Unlabelled CyPA, CyPB or CyPC were tested for their ability to compete with "#&I-CyPB for binding to the receptor. To this end, cells were incubated with recombinant "#&I-CyPB in the presence of increasing concentrations of unlabelled cyclophilins ( Figure 1 
Competitive binding assays with the synthetic peptides corresponding to CyPB extremities
The interactions of the synthetic peptides corresponding to the first 24 N-terminal amino acid residues (D"EKKKGPKVT-VKVYFDLRIGDEDV#%) and to the last 15 C-terminal amino acid residues (C"(!GKIEVEKPFAIAKE")%) of CyPB ( Figure 2 
Competitive binding assays with modified CyPB and modified Nterminal peptide
CyPB was modified either by AMCA-HPDP for targeting the single cysteine residue, or by p-hydroxyphenylglyoxal for the arginine residues. The modified proteins were then used as competitors in competitive experiments carried out as described above.
Modification of cyclophilins with p-hydroxyphenylglyoxal
To investigate the possible involvement of arginine residues in the binding of CyPB to Jurkat T-cells, CyPB was treated with phydroxyphenylglyoxal under mild conditions. This compound modifies proteins by reacting highly selectively with the guanidinyl group of the arginine residues to form a stable complex [24] . The p-hydroxyphenylglyoxal reaction with arginine residues in proteins is accompanied by a marked spectral change. Figure  4 shows the UV absorption spectra of p-hydroxyphenylglyoxaltreated CyPB and CyPB L"(I ; R")A . The CyPB spectrum ( Figure 4 , curve a) has a maximum absorption at 335 nm as expected for a p-hydroxyphenylglyoxal-modified protein.
A molar absorption coefficient of 1.85i10% M −" :cm −" at pH 9.0 was used to determine the amount of modified arginine residues [24] . The extent of reaction of arginine residues with p-hydroxyphenylglyoxal calculated using this value and the absorption at 335 nm, was 1.15 residues per molecule. In contrast, the modified CyPB L"(I ; R")A spectrum (Figure 4, curve b) , which lacks the 
Figure 3 Competitive binding assays of 125 I-CyPB to Jurkat T-cells with synthetic peptides corresponding to CyPB extremities
Figure 4 UV absorption spectra of p-hydroxyphenylglyoxal-treated cyclophilins
Curve (a) : CyPB treated with p-hydroxyphenylglyoxal at pH 9.0 for 1 h at 25 mC. Curve (b) : CyPB L17I;R18A treated with p-hydroxyphenylglyoxal under the same conditions. The spectra were recorded at pH 9.0 and at room temperature.
Arg"), showed only a weak absorption at 335 nm, corresponding to 0.2 modified arginine residue per molecule. These values confirm that only a limited derivatization has taken place under the conditions used since a total of seven and six arginine residues are present in CyPB and CyPB L"(I ; R")A respectively.
Competitive binding assays with modified CyPB, CyPB L17I ;R18A or the Nterminal peptide
The effect of the modification of CyPB with p-hydroxyphenylglyoxal on the association to the Jurkat T-cells is shown in Figure 5 . The data demonstrate that the modification of one arginine residue of CyPB is accompanied by a loss of the binding to the Jurkat T-cells. A confirmation was obtained by modifying the only arginine residue of the D"EKKKGPKVTVKVYF-DLRIGDEDV#% peptide. The modified peptide also failed to compete with "#&I-CyPB for binding to its receptor ( Figure 5 ).
The efficiency of the CyPB labelling by AMCA-HPDP was controlled by the measurement of absorbances at 280 nm and 345 nm. A fluorochrome\protein ratio of 0.82 was obtained, consistent with the fact that CyPB has only one cysteine residue, localized at position 170. As shown in Figure 5 , derivatization of CyPB with AMCA-HPDP did not significantly interfere with its binding to Jurkat T-cells. Less than 20 % of deviation of the IC &! value was observed using AMCA-HPDP-labelled CyPB as a competitor, even in 500 molar excess.
Competitive binding assays with CyPB mutants
In order to further confirm the importance of the N-terminus of CyPB in the interaction with the receptor, two mutant forms were engineered and tested. In one mutant the N-terminal region specific to CyPA was replaced by the N-terminal CyPB specific region to give a CyPB\A chimaera. In the second mutant, the L"(R") residues of CyPB were exchanged for the IA residues located at equivalent positions in the N-terminal region of CyPA, to give the CyPB L"(I ; R")A mutant. Competitive binding experiments were carried out to test the affinity of these CyPB mutants for the Jurkat T-cell receptor ( Figure 6 ). The CyPB\A chimera was able to inhibit the binding of "#&I-CyPB but only to a certain extent. The IC &! of CyPB\A chimera was estimated to be 21 µM and corresponds to a 70-fold lower affinity for the receptor than CyPB. In contrast, the CyPB L"(I ; R")A mutant inhibited "#&I-CyPB binding as well as CyPB did. The IC &! values of CyPB and CyPB L"(I ; R")A binding to the specific receptor differ by less than 20 %.
DISCUSSION
Although CyPA and CyPC are closely related to CyPB, they do not bind to the Jurkat T-cell receptor [21] . This is accountable for CyPA which is exclusively cytosolic and exhibits several marked structural divergences from CyPB. It is more surprising for CyPC since it shares more than 70 % sequence identity with CyPB. It has so far not been demonstrated that CyPC is secreted despite the presence of a signal sequence which directs it to the secretory pathway [9, 15] . The only known ligand for CyPC, the CyPCassociated protein (CyCAP), is also a protein which follows the secretory pathway [25] . Our results demonstrate the fine specificity of the interaction between CyPB and its receptor on Jurkat T-cells.
Major sequence differences between CyPA and CyPB are located in the N-and C-terminal regions, which were therefore obvious choices for use in competitive binding experiments. Antibodies raised against the corresponding peptides D"EKKKGPKVTVKVYFDLRIGDEDV#% and C"(!GKIEVE-KPFAIAKE")% do not recognize CyPA [20] , testifying to the specificity of these peptides. While the C"(!GKIEVEKPFA-IAKE")% peptide had no inhibitory effect on the binding of "#&I-CyPB to Jurkat T-cells, the D"EKKKGPKVTVKVYFDLR-IGDEDV#% peptide inhibited the binding down to 38 % of control levels. The incomplete inhibition observed for this peptide (only a 5-fold increase of IC &! ) may be explained by secondary structure differences and\or by the fact that all the residues involved in the interaction with the receptor are not included in this peptide. The comparison of the X-ray structures of CyPA and CyPB shows that the proteins share the same overall conformation except for two loops, one of them located between the residues 19 to 24 of CyPB [26] . The area covered by the D"EKKKGPKV-TVKVYFDLRIGDEDV#% peptide therefore encompasses one of the two main structural differences between CyPA and CyPB, consistent with the fact that, unlike CyPB, CyPA does not bind to Jurkat T-cells [21] .
Chemical modification of arginine residues has been proved valuable in understanding structure-function relationships in proteins [27] . In our study, we modified the arginine residues of CyPB with p-hydroxyphenylglyoxal. This compound specifically neutralizes the positive charge of arginine by complexation with the guanidinyl group but leaves the other amino acids unchanged. Our results clearly demonstrate that the derivatization of one arginine residue in CyPB abolishes its capacity to inhibit the binding of "#&I-CyPB to Jurkat T-cells. The arginine residue modified by p-hydroxyphenylglyoxal in CyPB might be Arg"), since only one arginine residue is modified in the protein under mild conditions and modified D"EKKKGPKVTVKVYFDL-RIGDEDV#% peptide is also unable to inhibit the binding of "#&I-CyPB to Jurkat T-cells. Another piece of evidence that Arg") is the modified arginine residue is provided by the treated CyPB L"(I ; R")A , which shows only 0.2 modified arginine residue. We surmise that this residue is particularly exposed at the surface of the molecule and easily modified by chemical agents. There is no corresponding arginine residue in CyPA. Taking all this together, it is likely that Arg") is at least indirectly involved in the interaction with the receptor. It is close enough to the CyPBinteracting site to prevent binding by steric hindrance when modified. Actually, it has been shown that two molecules of phydroxyphenylglyoxal react with one arginine residue to form a high size complex [24] .
Labelling a protein in the vicinity of the receptor-binding site by a fluorophore is a good tool with which to inhibit proteinprotein interaction by masking the interaction site. CyPB has a single cysteine residue located at position 170 just before the Cterminal extension. Furthermore, the N-and C-terminus ends of CyPB are aggregated together and point away from the molecular bulk to form a β-strand [25] . To hide this part of the protein, AMCA-HPDP was used because of its high specificity for sulphydryl groups and the presence of a six-carbon arm creating a high steric hindrance. But, despite a fluorophore\protein ratio of 0.82, the labelling of CyPB by AMCA-HPDP had only a minor effect on the binding to the Jurkat T-cell receptor, indicating that the receptor binding site is not in the area close to the modified cysteine residue. This cysteine is also found in the C"(!GKIEVEKPFAIAKE")% peptide, and the absence of inhibitory effect of this peptide is in agreement with this finding.
Two CyPB mutants were designed to complete the results described above. In the CyPB\A chimaera, the N-terminus of CyPB up to Val#% was exchanged for the corresponding region of CyPA. The chimaeric protein binds to the Jurkat receptor, however, with a 70-fold lower affinity than CyPB. There are at least two possible explanations for this. First, the lower affinity might be due to a different conformation of D"EKKKGPKV-TVKVYFDLRIGDEDV#%, when placed in CyPA instead of CyPB. This is supported by the fact that the IC &! of the free D"EKKKGPKVTVKVYFDLRIGDEDV#% peptide is 10-fold higher than the one measured for the CyPB\A chimaera. Secondly, it is possible that another part of CyPB is involved in the interaction with the receptor. This is observed for instance with interleukin-8 (IL-8) binding to both its A and B type receptors. While the E%LR' sequence is necessary for the binding, the Tyr"$ and Lys"& residues are required for a high-affinity binding [28] . There are some similarities between the cyclophilins and IL-8. In fact, like the cyclophilins, IL-8 is able to specifically bind to CsA. IL-8 was described as a dimeric molecule with a three-dimensional structure resembling that of the cyclophilins [29] . Moreover, the E%LR' consensus sequence of IL-8 is quite similar to the D"'LR") sequence of CyPB, suggesting that these residues may be important for the CyPB interaction with the receptor. In contrast to the results obtained when using p-hydroxyphenylglyoxal, a CyPB mutant where the L"(R") sequence was modified to the corresponding I""A"# sequence of CyPA binds to the Jurkat receptor as well as CyPB does, suggesting that neither Leu"( nor Arg") directly interact with the receptor. Consequently, the best explanation for the loss of competitive binding of Arg-derivatized CyPB is probably that the modification forms a complex sufficiently large and close to the binding site to prevent the interaction with the receptor.
In conclusion, our results demonstrate that the first 24 amino acid residues of CyPB are involved in the binding to Jurkat Tcells. This region contains a single arginine residue, preventing the interaction with the receptor when derivatized but not when mutated to Ala. The use of molecular modelling to visualize the effects of the chemical modifications of arginine and cysteine residues will be another step towards a better characterization of the CyPB-binding site. Site-directed mutagenesis will allow a more precise characterization of the amino acid residues directly implicated in the interaction with the receptor. We also confirm the specificity of the Jurkat T-cell binding sites for CyPB, as opposed to CyPA, in keeping with the fact that CyPB is secreted in biological fluids such as blood and milk and that CyPA is exclusively cytosolic. CyPC does not bind to Jurkat T-cells either despite the presence in its N-terminal region of a stretch highly similar to the 24 N-terminal amino acids of CyPB. Interestingly, the amino acid corresponding to Arg") of CyPB is conserved in CyPC. A fine analysis of the differences between the different cyclophilins should provide further clues as to the residues involved in receptor binding by CyPB.
